Australia's most trusted
source of pharma news
Monday, 09 February 2026
Posted 9 February 2026 AM
Anthina Life Sciences has registered the first generic version of not-for-profit pharma MS Health’s abortion pill MS-2 Step.
MS-2 Step’s earnings have been on the rise since a landmark decision to broaden access to treatment in 2023. In 2025, MS-2 Step earned the MS Health $19.4 million in pre-rebate PBS benefits, up 23.5 per cent from the previous year.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.